The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

French drugmaker Sanofi said the U.S. Food and Drug Administration ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the ...

May 27 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against ...